Davinder Brar a former managing director at Ranbaxy Laboratories, spoke to Business Standard on phone from New Delhi on his views on Ranbaxy founders' decision to sell their stake.

<tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>
</p><p class='TableClas'>Ranbaxy's founders Malvinder Singh and his family sold their entire stake -- 34.82 per cent stake -- in the company to Japan's Daiichi Sankyo for as much as $4.6 billion. 
</p><p class='TableClas'>
</p><p class='TableClas'><STRONG>Your views on the Ranbaxy-Daiichi deal

Web excl: D S Brar on the Ranbaxy-Daiichi deal

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News